Tacrolimus Conversion in CYP3A5*1 Expressers: From Immediate-Release to LCP Formulation
These results suggest that CYP3A5 genotype should be considered when adjusting the tacrolimus dose during conversion from Tac-IR to Tac-LCP. C0 values may not adequately reflect the higher exposure observed in CYP3A5*1 expressers, highlighting the importance of AUC0-24h in guiding dose adjustment.
Authors
- Anna Vidal‐Alabró (ORCID: https://orcid.org/0000-0001-7695-2372)
- Helena Colom (ORCID: https://orcid.org/0000-0002-7259-0199)
- Laia Oliveras (ORCID: https://orcid.org/0009-0002-5317-7304)
- Núria Montero (ORCID: https://orcid.org/0000-0002-5123-4603)
- Josep M. Cruzado (ORCID: https://orcid.org/0000-0003-1388-8558)
- Edoardo Melilli (ORCID: https://orcid.org/0000-0001-6965-3745)
- Anna Manonelles (ORCID: https://orcid.org/0000-0003-2456-388X)
- Pere Fontova (ORCID: https://orcid.org/0000-0002-1352-3084)
- Alexandre Favà (ORCID: https://orcid.org/0000-0003-1664-6001)
- Gema Cerezo
- Carlos Couceiro (ORCID: https://orcid.org/0000-0002-8303-8703)
- Beatriz Fernández-Alarcón
- Josep M. Grinyó (ORCID: https://orcid.org/0000-0002-7435-3808)
- Ana Coloma (ORCID: https://orcid.org/0000-0002-1773-9560)
- Núria Lloberas (ORCID: https://orcid.org/0000-0002-3387-5757)
- Sergi Codina (ORCID: https://orcid.org/0000-0002-2313-6109)
- Joan Torras
- Zeyar Mohammed Ali
Institutions
- American Pharmacists Association (US)
- Bellvitge University Hospital (ES)
- Institut d'Investigació Biomédica de Bellvitge (ES)
- Universitat de Barcelona (ES)
Publication Details
- Journal
- Therapeutic Drug Monitoring
- Published
- 2025-12-08
- DOI
- https://doi.org/10.1097/ftd.0000000000001411
- Primary Topic
- Pharmacogenetics and Drug Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00